| Years | Dec
2001 |
Dec
2000 |
Dec
99 |
Dec
98 |
Dec
97 |
Dec
96 |
Dec
95 |
97-01
5-yr Annual |
| Revenue (Mln US$) | 2,202 | 1,736 | 1,401 | 1,151 | 1,017 | 969 | 918 | |
| Revenues Growth % | 27 | 24 | 22 | 13 | 5 | 6 | 15 | 13 |
| Net Income (Mln US$) | 405 | 325 | 247 | 182 | 129 | 118 | 146 | |
| Special Items (Mln US$) | -255 | -336 | -1,404 | |||||
| Earning Growth % | 26 | 30 | 35 | 41 | 9 | -20 | 18 | 15 |
| Net Profit Margin % | 18 | 18 | 18 | 16 | 13 | 12 | 16 | |
| Gross Margin % | 84 | 83 | 85 | 87 | 89 | 88 | 88 | |
| Return on Equity % | 7 | 6 | 6 | 9 | 6 | 7 | 9 | |
| Debt / Equity % | 20 | 18 | 24 | 22 | 23 | 24 | 26 | |
| EPS | 0.76 | 0.61 | 0.47 | 0.35 | 0.26 | 0.24 | 0.30 | |
| R&D (Mln US$) | 526 | 490 | 367 | 396 | 470 | 471 | 363 | |
| Research / Sales % | 24 | 28 | 26 | 34 | 46 | 49 | 40 |
Market Cap.:
$ 26 billion
(Feb 8, 2002)
Cash & Short Term Investment:
$ 1,348 millions (Dec 31, 2001)
Total Assets:
$ 7,137 millions
Long Term Debt:
$ -
Total Liabilities:
$ 1,218 millions
Shareholders Equity:
$ 5,920 millions
Price: $ 48 (Feb
8, 2002)
P/E: 63
(based on the average EPS $0.76 of the last 2 years and the consensus estimate
for 2002.)
Profile
- a pioneer US biotech drug company founded in 1976
- focus on cancers and heart diseases, the first 2 killers in the US
- Roche, a Swiss drug maker, is holding 58% of its stocks
- total revenues in 2001: US$ 2.2 billion
- ranked 69 in Forbes 500 in market value
- average EPS growth of 30% over the past 3 years
- the company is aiming at a 25% annual earning growth for the next
5 years
- stock code: DNA
Products on the Market
| Product | Target | Sales in 2001 (millions $) | % Change | Remarks |
| Herceptin | Breast cancer | 347 | +26% | Launched in Sep 1998.
Monoclonal antibody targeting HER-2 proteins associated with breast cancer that spread out. Marketed by Hoffmann-La Roche outside the U.S. |
| Rituxan | Non-Hodgkin's lymphoma | 819 | +84% | Introduced in Dec 1997.
Collaborated with IDEC. |
| Activase / TNKase / Cathflo Activase | Cariovascular diseases | 197 | -4% | TNKase was introduced in June 2000.
Face competition from Centocor's Retavase. |
| Nutropin Depot, Nutropin AQ, Nutropin and Protropin | Growth hormones | 250 | +10% | Nutropin Depot was launched in June 2000. |
| Pulmozyme | Cystic fibrosis | 123 | +1% |
Major Development Products
| Product | Clinical Trial | Disease | Remarks | Estimate of Completion |
| Xolair Anti-IgE Antibody | Pending FDA approval | Allergic Asthma | Approval delayed by FDA. New studies required. Approval may be extended to late 2003. | 2003 |
| Rituxan Antibody | Phase III | Intermediate and high grade non-Hodgkin's lymphoma | Received approval | 2002 |
| Nutropin Depot | Phase III | Growth hormone deficiency in adults | Partnered with Alkermes | 2003 |
| Herceptin Antibody | Phase III | Adjuvant early stage breast cancer | 2006 | |
| Avastin - Anti-VEGF Antibody | Phase III | Serveral types of solid tumor cancers | Blocks the growth of blood vessels that feed cancerous tumors | 2002-2005 |
| Xanelim Anti-CD11a Antibody | Phase III | Moderate to severe psoriasis | Partnered with XOMA, filing delayed to Mid 2002. | 2002 |
| Tarceva | Phase III | Non small cell Lung Cancer / Pancreatic Cancer | Partner with OSI and Roche | 2003 |
| Cathflo Activase | Phase III | Prevention of Catheter Occlusion in Hemodialysis |